Aditxt Partners With CLX Health to Offer AditxtScore™ for COVID-19 Immune Monitoring Service Through CLX’s TrustAssure™ Platform
November 03 2021 - 9:00AM
Business Wire
- Access to over 5,000 U.S.
Locations
- Reaching 15,000 Locations Globally in over
81 countries worldwide
- Service to dozens of airlines that enter
over 75 countries
Aditxt, Inc. (Nasdaq: ADTX), (“Aditxt” or the “Company”) a
biotechnology innovation company with a mission to improve the
health of the immune system, announced today a partnership with CLX
Health, a developer of cloud-based solutions. The goal of this
partnership is to accelerate the market availability of
AditxtScore™ for COVID-19 through CLX Health’s TrustAssure Solution
Suite. TrustAssure Solution Suite is a multi-stakeholder engagement
platform that consumers, laboratories, healthcare providers, health
plans, and public health authorities can access to communicate
vital health information for real-time risk assessment to manage
the COVID-19 pandemic and other public health emergencies.
Aditxt will be working with CLX Health to expand sample
collection sites for AditxtScore™ for COVID-19 through the
TrustAssure global network of COVID-19 testing partners. The
seamless partnership with CLX Health will offer additional methods
for scheduling, testing, and reporting results through its HIPAA
compliant platform. TrustAssure provides travelers answers on the
risk of where they have been and where they are going. AditxtScore™
for COVID-19 adds further insight by providing individuals with a
more complete immune profile, specific to COVID-19. AditxtScore™
benefits travelers seeking to better understand and manage their
immune status ahead of travel, enabling them to take more control
of their own personal health risks.
“The partnership with CLX Health is an important step in our
AditxtScore™ worldwide rollout and will increase the brand
recognition of AditxtScore™ as a leading immune monitoring
service,” said Amro Albanna, Co-founder and Chief Executive Officer
of Aditxt. “TrustAssure is a leader in the COVID-19 testing space
for work, entertainment and travel related engagements. We are
pleased to work with the team at CLX Health in creating alliances
through their industry-leading platform,” Mr. Albanna added.
CLX Health’s Global Lab Director Bob Fleury commented,
“AditxtScore™ for COVID-19 is a unique, precise, and comprehensive
COVID-19 test that delivers a lot more than a negative or positive
result, so we are thrilled to partner with Aditxt to add
AditxtScore™ for COVID-19 to our TrustAssure platform. This kind of
immune monitoring tool is an essential component for managing the
COVID-19 pandemic.”
About AditxtScore™ for COVID-19
While it is impossible to ensure every encounter is infection
free, AditxtScore™ for COVID-19 can help individuals gain a better
understanding of their immunity status. Aditxt’s monitoring service
is based on a comprehensive evaluation of the immune response to
the COVID-19 virus or vaccine. AditxtScore™ provides meaningful
information to help understand one’s personal immune response to
COVID and not just that of the population collectively. For more
information visit: www.aditxtscore.com
About CLX Health / TrustAssure™
CLX Health, a privately and wholly owned SiriusIQ company,
delivers a clinically sound, cloud-based, multi-stakeholder
solution which manages a COVID-19 testing ecosystem of physicians,
clinics, hospitals, laboratories, and consumers. CLX Health’s
TrustAssure™ Global Network of COVID-19 testing partners and
providers offer over 5,000 locations across the United States and
greater than 15,000 locations in over 81 countries worldwide to
support various “ready to” solutions for work, entertainment, and
travel related engagements. For more information, please visit
https://www.trustassure.com
About Aditxt
Aditxt is developing technologies specifically focused on
improving the health of the immune system through immune monitoring
and reprogramming. Aditxt’s immune monitoring technology is
designed to provide a personalized comprehensive profile of the
immune system. Aditxt’s immune reprogramming technology is
currently at the pre-clinical stage and is designed to retrain the
immune system to induce tolerance with an objective of addressing
rejection of transplanted organs, autoimmune diseases, and
allergies. For more information, please visit: www.aditxt.com
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s intellectual property position; the Company’s ability
to develop commercial functions; expectations regarding product
launch and revenue; the Company’s results of operations, cash
needs, spending, financial condition, liquidity, prospects, growth
and strategies; the industry in which the Company operates; and the
trends that may affect the industry or the Company. Forward-looking
statements are not guarantees of future performance and actual
results may differ materially from those indicated by these
forward-looking statements as a result of various important
factors, as well as those risks more fully discussed in the section
titled “Risk Factors” in the Company’s most recent Annual Report on
Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211103005449/en/
Aditxt, Inc. ir@aditxt.com
Edison Investor Relations Maxwell Colbert
mcolbert@edisongroup.com
CLX Health Alyson Kuritz Alyson@0to5.com
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From May 2024 to Jun 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
From Jun 2023 to Jun 2024